Enochian Biosciences Inc ENOB
We take great care to ensure that the data presented and summarized in this overview for Enochian Biosciences Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENOB
View all-
Vanguard Group Inc Valley Forge, PA3.92MShares$18 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA438KShares$2.01 Million0.0% of portfolio
-
Morgan Stanley New York, NY375KShares$1.73 Million0.0% of portfolio
-
Black Rock Inc. New York, NY314KShares$1.45 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY306KShares$1.41 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny294KShares$1.35 Million0.0% of portfolio
-
Citigroup Inc187KShares$862,2880.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA178KShares$819,2180.0% of portfolio
-
Jane Street Group, LLC New York, NY134KShares$615,6590.0% of portfolio
-
Jpmorgan Chase & CO New York, NY120KShares$553,6000.0% of portfolio
Latest Institutional Activity in ENOB
Top Purchases
Top Sells
About ENOB
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Insider Transactions at ENOB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Anderson Wittekind William |
SELL
Open market or private sale
|
Indirect |
50,000
-3.81%
|
$50,000
$1.58 P/Share
|
|
Feb 20
2024
|
Rene Sindlev Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
471,699
+3.35%
|
$0
$0.53 P/Share
|
|
Feb 13
2024
|
Ole Abildgaard > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,436,190
+30.32%
|
-
|
|
Feb 13
2024
|
Rene Sindlev Director |
BUY
Conversion of derivative security
|
Indirect |
701,260
+5.07%
|
-
|
|
Oct 23
2023
|
Avram Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000,000
+50.0%
|
-
|
|
Oct 03
2023
|
Ole Abildgaard > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
500,000
+6.33%
|
-
|
|
Aug 22
2023
|
Ole Abildgaard > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
500,000
+6.76%
|
-
|
|
Jun 26
2023
|
Rene Sindlev Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,886,794
+13.18%
|
$0
$0.53 P/Share
|
|
Mar 17
2023
|
Rene Sindlev Director |
BUY
Grant, award, or other acquisition
|
Indirect |
877,193
+7.68%
|
$877,193
$1.14 P/Share
|
|
Oct 13
2022
|
Anderson Wittekind William |
BUY
Other acquisition or disposition
|
Indirect |
1,216,467
+48.08%
|
-
|
|
Oct 13
2022
|
Weird Science LLC |
BUY
Other acquisition or disposition
|
Direct |
1,216,467
+48.08%
|
-
|
|
Jun 08
2022
|
Rene Sindlev Director |
SELL
Other acquisition or disposition
|
Indirect |
253,493
-100.0%
|
-
|
|
May 18
2022
|
Rene Sindlev Director |
BUY
Open market or private purchase
|
Indirect |
253,493
+50.0%
|
$2,027,944
$8.0 P/Share
|
|
May 18
2022
|
Serhat Gumrukcu > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
253,493
-1.02%
|
$2,027,944
$8.0 P/Share
|
|
Apr 15
2022
|
Weird Science LLC |
SELL
Other acquisition or disposition
|
Direct |
4,961,363
-98.08%
|
-
|
|
Apr 15
2022
|
Carl Forest Sandler |
BUY
Other acquisition or disposition
|
Direct |
992,273
+18.24%
|
-
|
|
Apr 15
2022
|
Carl Forest Sandler |
SELL
Other acquisition or disposition
|
Indirect |
3,969,090
-53.45%
|
-
|
|
Apr 11
2022
|
Weird Science LLC |
BUY
Other acquisition or disposition
|
Direct |
97,032
+1.88%
|
-
|
|
Apr 11
2022
|
Anderson Wittekind William |
BUY
Other acquisition or disposition
|
Indirect |
97,032
+1.88%
|
-
|
|
Mar 22
2022
|
Carl Forest Sandler |
SELL
Open market or private sale
|
Direct |
1,927
-0.06%
|
$17,343
$9.06 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 4.14M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 472K shares |
| Grant, award, or other acquisition | 2M shares |
| Open market or private sale | 50K shares |
|---|